Efficacy and safety of live combined Bacillus subtilis and Enterococcus faecium in patients with Helicobacter pylori infection: A meta-analysis of randomized controlled trials Authors: Chenghai Yang, Bingyun Lu, Cangui Zhang, Anjiang Wang, Ye Chen Published: 2026 ABSTRACT Highlights•A meta-analysis with 26 randomized controlled trials containing 3,536 patients.•LCBE supplementation increases Helicobacter pylori eradication rate.•LCBE supplementation reduces total and gastrointestinal adverse events.•LCBE supplementation increases Immunoglobulin (Ig)A and IgG levels.•LCBE supplementation reduces tumor necrosis factor-α and interleukin-6 levels. Introduction Helicobacter pylori (H. pylori) infection affects ⁓50% of the global population and is the leading cause of chronic gastritis, peptic ulcers and gastric cancer.1 Current recommended therapies are antibiotic-based triple or quadruple regimens.2, 3, 4 However, the occurrence of antibiotic resistance impairs the efficacy of these therapies, which leads to declining eradication rates.5,6 In addition, adverse effects associated with antibiotic use, including gastrointestinal disturbances and microbial dysbiosis, increase safety concerns.7,8 Therefore, exploring the development of potential adjunctive regimens to improve efficacy while minimizing adverse events is crucial in enhancing the management of patients with H. pylori infection. Probiotics are beneficial live microorganisms that are commonly used as an adjunctive regimen in antibiotics for the treatment of H. pylori infection.9 Probiotics can enhance H. pylori eradication by producing antibacterial substances, reducing adhesion, attenuating inflammation and enhancing immune responses.9 Furthermore hand, probiotics can also regulate the gut microbiota to alleviate adverse events caused by antibiotics in patients with H. pylori infection.10 Live Combined Bacillus subtilis and Enterococcus faecium (LCBE), a probiotic formulation, possesses the ability to regulate gut microbiota and gastrointestinal inflammation.11,12 Certain Randomized Controlled Trials (RCTs) have investigated the efficacy and safety of LCBE-containing regimens in patients with H. pylori infection.13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 Nevertheless, the findings of these RCTs are inconsistent. In addition, the sample sizes of certain RCTs were relatively small, which impaired the statistical power. Therefore, to provide a holistic representation of the efficacy and safety of LCBE in patients with H. pylori infection, a meta-analysis is required. This meta-analysis aimed to compare the efficacy and safety of interventions with or without LCBE in patients with H. pylori infection. Materials and methods Registration This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.39 The protocol was retrospectively registered in PROSPERO (CRD420261430266). Literature strategy A comprehensive search was conducted across multiple databases, including Web of Science, PubMed, Cochrane Library, China National Knowledge Infrastructure, Wan Fang, and China Science and Technology Journal Database (VIP). The search utilized keywords such as “Bacillus Subtilis and Enterococcus Faecium”, “Live Combined Bacillus Subtilis and Enterococcus Faecium”, “Medilac-Vita”, “Medilac-S”, “Probiotics”, “Helicobacter pylori infection”, “H. pylori infection”, and “HP infection”. The search was limited to studies published prior to February 2025. To ensure comprehensiveness, the references of the selected studies were manually reviewed to identify potentially relevant studies. The detailed search strategies for all databases are presented in Supplementary Table 1.Table 1Overview of included studies.Study IDDemographicsaSample sizeDisease typeInterventionLCBE regimenFirst author (publication year)Experimental groupControl groupExperimental groupControl groupExperimental groupControl groupLiu ZP (2009)13Age (all): PU: 35.6±11.5; CG: 44.3±9.3100100PU or CGLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex (all): PU: 54/26; CG: 55/65Zhang QZ (2012)14Age: 46.6±10.7Age: 49.7±12.36066PU or CGLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex: 33/27Sex: 35/31Hu LY (2013)15Age (all): 36.5±7.2118112Not reportLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex (all): 112/118Duan ZY (2014)16Age: 44.2±3.8Age: 42.4±5.88080Not reportLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 1-weekSex: 42/38Sex: 39/41He QL (2014)17Age (all): DU: 38.2±11.5; CEG: 40.4±10.4150150DU or CEGLCBE + Quadruple therapyQuadruple therapy500 mg, bid; Before meal; 10-daysSex (all): 209/91Jiang ZY (2014)18Age (all): 36.5±7.25046PULCBE + Triple therapyTriple therapy500 mg, tid; After meal; 10-daysSex (all): 52/44Du HW (2015)19Age (all): 60.0‒87.0112112CEG, GU, or DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex (all): 128/96Zhang JF (2015)20Age: 40.2±3.2Age: 40.1±3.0102102PULCBE + Quadruple therapyQuadruple therapy500 mg, bid; Before meal; 10-daysSex: 64/38Sex: 66/36Cui Y (2016)21Age: 38.9±14.0Age: 34.2±13.33031Not reportLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 15/15Sex: 15/16Oh B (2016)22Age: 51.7±4.8Age: 49.3±3.61010GU or DULCBE + Triple therapyTriple therapybid; 2-weeksSex: 7/3Sex: 7/3Xu P (2016)23Age: 44.0±10.0Age: 42.0±11.03436Not reportLCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 18/16Sex: 19/17Luo QT (2017)24Age: 41.5±12.9Age: 39.4±13.18080DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; Before meal; 2-weeksSex: 52/28Sex: 50/30Wang Y (2017)25Age: 45.5±6.5Age: 46.0±5.6135132FDLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 69/66Sex: 65/67Zhou QF (2017)26Age: 70.5±7.1Age: 72.5±7.44646PULCBE + Quadruple therapyQuadruple therapy500 mg, tid; After meal; 2-weeksSex: 24/22Sex: 27/19Chen X (2018)27Age: 67.3±7.5Age: 66.6±7.25050Not reportLCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 34/16Sex: 31/19Jin L (2018)28Age: 38.6±10.7Age: 36.4±13.36060CG or CEGLCBE + Quadruple therapyQuadruple therapy500 mg, tid; Before meal; 2-weeksSex: 38/22Sex: 36/24Xue QY (2018)29Age: 40.1±12.5Age: 39.8±12.98282DULCBE + Quadruple therapyQuadruple therapy250 mg, bid; Before meal; 10‒14 daysSex: 48/34Sex: 50/32Zhang DH (2018)30Age: 40.1±3.6Age: 41.5±3.16060DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 42/18Sex: 46/14Chen CJ (2019)31Age: 42.5±4.6Age: 41.6±5.65050CG or CEGLCBE + Triple therapyTriple therapy1000 mg, tid; Before meal; 4-weeksSex: 27/23Sex: 26/24Wu L (2019)32Age: 45.2±11.6Age: 45.5±8.42020DULCBE + Triple therapyTriple therapy500 mg, tid; 6-weeksSex: 12/8Sex: 13/7Ye MQ (2019)33Age: 38.1±4.0Age: 37.7±3.85050DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 8-weeksSex: 27/23Sex: 29/21Chang XL (2021)34Age: 38.8±1.6Age: 38.9±2.07575DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 47/28Sex: 46/29Zhao JY (2022)35Age: 8.3±2.3Age: 9.1±3.56060Not reportLCBE + Triple therapyTriple therapy1 g, bid; 2-weeksSex: 36/24Sex: 40/20Li XM (2024)36Age: 41.5±2.8Age: 41.8±2.94848Not reportLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 29/19Sex: 28/20Li XY (2024)37Age: 38.0±6.5Age: 37.5±6.95858CG, GU, or DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 32/26Sex: 30/28Lin CC (2024)38Age: 32.6±3.3Age: 32.6±3.25050Not reportLCBE + Dual therapyDual therapy500 mg, bid; After meal; 2-weeksSex: 33/17Sex: 32/18PU, Peptic Ulcer; CG, Chronic Gastritis; LCBE, Live Combined Bacillus subtilis and Enterococcus faecium; DU, Duodenal Ulcer; CEG, Chronic Erosive Gastritis; GU, Gastric Ulcer; FD, Functional Dyspepsia.Special statement of superscript “a”: 1) Age was described as mean ± standard deviation, or range. The unit of age was “years”. 2) Sex was described as the number of males/number of females. 3) The “all” in parentheses indicated that the data described the overall study population, and there was no separate report of experimental and control groups in the original study. Table 1Overview of included studies.Study IDDemographicsaSample sizeDisease typeInterventionLCBE regimenFirst author (publication year)Experimental groupControl groupExperimental groupControl groupExperimental groupControl groupLiu ZP (2009)13Age (all): PU: 35.6±11.5; CG: 44.3±9.3100100PU or CGLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex (all): PU: 54/26; CG: 55/65Zhang QZ (2012)14Age: 46.6±10.7Age: 49.7±12.36066PU or CGLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex: 33/27Sex: 35/31Hu LY (2013)15Age (all): 36.5±7.2118112Not reportLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 2-weeksSex (all): 112/118Duan ZY (2014)16Age: 44.2±3.8Age: 42.4±5.88080Not reportLCBE + Triple therapyTriple therapy500 mg, tid; After meal; 1-weekSex: 42/38Sex: 39/41He QL (2014)17Age (all): DU: 38.2±11.5; CEG: 40.4±10.4150150DU or CEGLCBE + Quadruple therapyQuadruple therapy500 mg, bid; Before meal; 10-daysSex (all): 209/91Jiang ZY (2014)18Age (all): 36.5±7.25046PULCBE + Triple therapyTriple therapy500 mg, tid; After meal; 10-daysSex (all): 52/44Du HW (2015)19Age (all): 60.0‒87.0112112CEG, GU, or DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex (all): 128/96Zhang JF (2015)20Age: 40.2±3.2Age: 40.1±3.0102102PULCBE + Quadruple therapyQuadruple therapy500 mg, bid; Before meal; 10-daysSex: 64/38Sex: 66/36Cui Y (2016)21Age: 38.9±14.0Age: 34.2±13.33031Not reportLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 15/15Sex: 15/16Oh B (2016)22Age: 51.7±4.8Age: 49.3±3.61010GU or DULCBE + Triple therapyTriple therapybid; 2-weeksSex: 7/3Sex: 7/3Xu P (2016)23Age: 44.0±10.0Age: 42.0±11.03436Not reportLCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 18/16Sex: 19/17Luo QT (2017)24Age: 41.5±12.9Age: 39.4±13.18080DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; Before meal; 2-weeksSex: 52/28Sex: 50/30Wang Y (2017)25Age: 45.5±6.5Age: 46.0±5.6135132FDLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 69/66Sex: 65/67Zhou QF (2017)26Age: 70.5±7.1Age: 72.5±7.44646PULCBE + Quadruple therapyQuadruple therapy500 mg, tid; After meal; 2-weeksSex: 24/22Sex: 27/19Chen X (2018)27Age: 67.3±7.5Age: 66.6±7.25050Not reportLCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 34/16Sex: 31/19Jin L (2018)28Age: 38.6±10.7Age: 36.4±13.36060CG or CEGLCBE + Quadruple therapyQuadruple therapy500 mg, tid; Before meal; 2-weeksSex: 38/22Sex: 36/24Xue QY (2018)29Age: 40.1±12.5Age: 39.8±12.98282DULCBE + Quadruple therapyQuadruple therapy250 mg, bid; Before meal; 10‒14 daysSex: 48/34Sex: 50/32Zhang DH (2018)30Age: 40.1±3.6Age: 41.5±3.16060DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 42/18Sex: 46/14Chen CJ (2019)31Age: 42.5±4.6Age: 41.6±5.65050CG or CEGLCBE + Triple therapyTriple therapy1000 mg, tid; Before meal; 4-weeksSex: 27/23Sex: 26/24Wu L (2019)32Age: 45.2±11.6Age: 45.5±8.42020DULCBE + Triple therapyTriple therapy500 mg, tid; 6-weeksSex: 12/8Sex: 13/7Ye MQ (2019)33Age: 38.1±4.0Age: 37.7±3.85050DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 8-weeksSex: 27/23Sex: 29/21Chang XL (2021)34Age: 38.8±1.6Age: 38.9±2.07575DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 47/28Sex: 46/29Zhao JY (2022)35Age: 8.3±2.3Age: 9.1±3.56060Not reportLCBE + Triple therapyTriple therapy1 g, bid; 2-weeksSex: 36/24Sex: 40/20Li XM (2024)36Age: 41.5±2.8Age: 41.8±2.94848Not reportLCBE + Triple therapyTriple therapy500 mg, tid; 2-weeksSex: 29/19Sex: 28/20Li XY (2024)37Age: 38.0±6.5Age: 37.5±6.95858CG, GU, or DULCBE + Quadruple therapyQuadruple therapy500 mg, tid; 2-weeksSex: 32/26Sex: 30/28Lin CC (2024)38Age: 32.6±3.3Age: 32.6±3.25050Not reportLCBE + Dual therapyDual therapy500 mg, bid; After meal; 2-weeksSex: 33/17Sex: 32/18PU, Peptic Ulcer; CG, Chronic Gastritis; LCBE, Live Combined Bacillus subtilis and Enterococcus faecium; DU, Duodenal Ulcer; CEG, Chronic Erosive Gastritis; GU, Gastric Ulcer; FD, Functional Dyspepsia.Special statement of superscript “a”: 1) Age was described as mean ± standard deviation, or range. The unit of age was “years”. 2) Sex was described as the number of males/number of females. 3) The “all” in parentheses indicated that the data described the overall study population, and there was no separate report of experimental and control groups in the original study. Overview of included studies. PU, Peptic Ulcer; CG, Chronic Gastritis; LCBE, Live Combined Bacillus subtilis and Enterococcus faecium; DU, Duodenal Ulcer; CEG, Chronic Erosive Gastritis; GU, Gastric Ulcer; FD, Functional Dyspepsia. Special statement of superscript “a”: 1) Age was described as mean ± standard deviation, or range. The unit of age was “years”. 2) Sex was described as the number of males/number of females. 3) The “all” in parentheses indicated that the data described the overall study population, and there was no separate report of experimental and control groups in the original study. Literature selection criteria Eligible studies met the following inclusion criteria: 1) Studies involving patients diagnosed with H. pylori infection; 2) Studies comparing efficacy or safety outcomes between groups treated with LCBE plus control treatment and those receiving control treatment alone; 3) Studies published in English or Chinese. Studies were excluded if they were reviews, meta-analyses, animal studies, case reports, or non-RCTs. In addition, studies were excluded if they involved overlapping patient populations or assessments by the same authors. The quality assessment of eligible studies was conducted using the ROB2.0 tool.40 Literature selection and quality assessment were independently performed by two researchers. Any disagreements were resolved through discussion, and a consensus was reached. Data extraction Data extraction comprised study details, such as the first author, year of publication, demographics, sample size and intervention. Outcomes related to efficacy, safety, immunity and inflammation evaluation of LCBE in treating H. pylori infection were systematically screened. The efficacy-related indicators included H. pylori eradication rate, while safety-related indicators involved adverse events and tolerability. Immunity and inflammation-related outcomes included common immune and inflammatory factor levels following treatment. Indicators reported in fewer than three studies were excluded from the meta-analysis to ensure robustness. Data extraction was conducted independently by two researchers using a standardized data collection form. Discrepancies were resolved through discussion and consensus. Statistical analysis Data analyses were conducted using R software (version 4.4.2). The effect sizes were pooled using the Odds Ratio (OR) and 95% Confidence Interval (95% CI) for categorical variables, such as H. pylori eradication rate and adverse event incidence. Continuous outcomes, such as immune and inflammatory factor levels, were analyzed using the Standardized Mean Difference (SMD) with a 95% CI. Random-effects models were used for all analyses to account for potential clinical and methodological heterogeneity across studies. Peters’ and Egger’s tests were utilized for assessment of publication bias for categorical and continuous variables, respectively, when at least 10 studies were available. A p < 0.05 was considered to indicate potential publication bias, prompting the use of the trim-and-fill method to adjust estimates. The robustness of the results was performed by sensitivity analyses, which were completed by sequentially excluding individual studies. Subgroup analyses were performed only when at least two studies were available within each subgroup. Results Study flow A total of 2,916 studies were identified through database searching. Then, 1,057 duplicated studies were excluded, and 1,859 studies were screened through title and abstract reading. Subsequently, 1,810 studies were excluded. Forty-nine studies were screened through full-text reading, and 23 studies were further excluded. Twenty-six studies that reported the efficacy or safety of LCBE in treating H. pylori infection were included in this meta-analysis13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 (Fig. 1).Fig. 1Study screen diagram. Study screen diagram. Characteristics of included studies This meta-analysis contained 3,536 patients. The age of the patients ranged from 8.3- to 87.0-years. LCBE was used in combination with triple therapy in 12 studies, with quadruple therapy in 13 studies and with dual therapy in 1 study. The dosage of LCBE was generally 500 mg, three times a day for 2-weeks in the majority of the studies. A total of 1,770 patients receiving LCBE-containing interventions were assigned to the experimental group and 1,766 patients receiving interventions without LCBE were assigned to the control group. The detailed characteristics of each included study are shown in Table 1. Risk of bias A total of 9, 25, 21, 25 and 22 studies were assessed as having low risk in bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome and bias in selection of the reported result, respectively. A total of 16, 1, 5, 1 and 4 studies were assessed as having some concerns in these 5 dimensions, respectively. One study was assessed as having high risk of bias arising from the randomization process. With regard to the overall risk of bias, 8 studies were assessed as having low risk, 17 studies were assessed as having some concerns and 1 study was assessed as having high risk (Fig. 2). The detailed information on risk of bias in each study is presented in Supplementary Figure 1.Fig. 2Quality assessment. Quality assessment. Efficacy A total of 25 studies reported the H. pylori eradication rate. No heterogeneity existed among studies (I2 = 23.101%). The random-effects model indicated that the H. pylori eradication rate in the experimental group was 2.403 times of that in the control group (OR = 2.403; 95% CI: 1.770, 3.261; p < 0.001). This finding suggested that LCBE-containing interventions enhanced eradication effect compared with interventions without LCBE (Fig. 3).Fig. 3Forest plot of H. pylori eradication rate. H. pylori, Helicobacter pylori. Forest plot of H. pylori eradication rate. H. pylori, Helicobacter pylori. In the triple therapy subgroup, the H. pylori eradication rate in the experimental group was 2.444 times of that in the control group (OR = 2.444; 95% CI: 1.577, 3.788; p < 0.001). In the quadruple therapy subgroup, the H. pylori eradication rate in the experimental group was 2.486 times of that in the control group (OR = 2.486; 95% CI: 1.587, 3.894; p < 0.001). Of note, as only one study evaluated LCBE in combination with dual therapy, it was included in the overall analysis but could not be analyzed as a separate subgroup (Supplementary Table 2). In subgroups of LCBE’s daily doses ≤ 1000 mg/day (OR = 2.105; 95% CI: 1.049, 4.226; p = 0.036) and 1500 mg/day (OR = 2.412; 95% CI: 1.678, 3.467; p < 0.001), H. pylori eradication rate was increased in experimental group than in the control group. However, in the subgroup of LCBE’s daily doses ≥ 2000 mg/day, H. pylori eradication rate was not different between the two groups (OR = 3.106; 95% CI: 0.955, 10.107; p = 0.060) (Supplementary Table 3). In subgroups of treatment durations of ≤ 2 (OR = 2.278; 95% CI: 1.655, 3.135; p < 0.001) and > 2 (OR = 3.938; 95% CI: 1.454, 10.663; p = 0.007) weeks, H. pylori eradication rate was increased in experimental group than in the control group (Supplementary Table 4). Safety A total of 17 studies reported the total adverse event rate without heterogeneity (I2 = 40.611%). According to the random-effects model, the total adverse event rate in the experimental group was 0.329-times of that in the control group (OR = 0.329; 95% CI: 0.222, 0.487; p < 0.001), suggesting that LCBE-containing interventions reduced total adverse event compared with interventions without LCBE (Fig. 4).Fig. 4Forest plot of total adverse event rate. Forest plot of total adverse event rate. Regarding gastrointestinal adverse events, 19, 17, 10, 9, 12 and 4-studies had data on the diarrhea rate, nausea and vomiting rate, abdominal distension rate, poor appetite rate, constipation rate and abdominal pain rate, respectively. No heterogeneity was observed (all I2 < 50.000%). The random-effects models revealed that in reference with the control group, the experimental group exhibited 0.251-times of the diarrhea rate (OR = 0.251; 95% CI: 0.142, 0.442; p < 0.001), 0.363 of the nausea and vomiting rate (OR = 0.363; 95% CI: 0.225, 0.588; p < 0.001), 0.299 of the abdominal distension rate (OR = 0.299; 95% CI: 0.139, 0.645; p = 0.002), 0.429 of the poor appetite rate (OR = 0.429; 95% CI: 0.240, 0.769; p = 0.004) and 0.421 of the constipation rate (OR = 0.421; 95% CI: 0.201, 0.882; p = 0.022) of the control group. However, the abdominal pain rate did not differ between the two groups (OR = 0.487; 95% CI: 0.101, 2.360; p = 0.372). The aforementioned findings suggested that LCBE-containing interventions significantly reduced diarrhea, nausea and vomiting, abdominal distension, poor appetite and constipation compared with interventions without LCBE (Fig. 5A‒F).Fig. 5Forest plots of gastrointestinal adverse events. Comparison of the diarrhea rate (A), nausea and vomiting rate (B), abdominal distension rate (C), poor appetite rate (D), constipation rate (E) and abdominal pain rate (F) between the experimental and control groups. Forest plots of gastrointestinal adverse events. Comparison of the diarrhea rate (A), nausea and vomiting rate (B), abdominal distension rate (C), poor appetite rate (D), constipation rate (E) and abdominal pain rate (F) between the experimental and control groups. With regard to non-gastrointestinal adverse events, 4, 6, 5, 4 and 4-studies reported taste disorders rate, headache rate, bitter taste rate, rash rate and dizziness rate, respectively, with lack of heterogeneity (all I2 = 0.000%). According to the random-effects models, the taste disorder rate in the experimental group was 0.337-times of that in the control group (OR = 0.337; 95% CI: 0.123, 0.920; p = 0.034). However, headache rate (OR = 0.481; 95% CI: 0.191, 1.211; p = 0.120), bitter taste rate (OR = 0.551; 95% CI: 0.225, 1.346; p = 0.191), rash rate (OR = 0.482; 95% CI: 0.141, 1.648; p = 0.244), and dizziness rate (OR = 0.690; 95% CI: 0.209, 2.279; p = 0.543) did not differ between the two groups. The aforementioned findings indicated that LCBE-containing interventions significantly decreased the taste disorder compared with interventions without LCBE (Fig. 6A‒E).Fig. 6Forest plots of non-gastrointestinal adverse events. Comparison of the taste disorder rate (A), headache rate (B), bitter taste rate (C), rash rate (D) and dizziness rate (E) between the experimental and control groups. Forest plots of non-gastrointestinal adverse events. Comparison of the taste disorder rate (A), headache rate (B), bitter taste rate (C), rash rate (D) and dizziness rate (E) between the experimental and control groups. Immunity and inflammation-related parameters A total of 5, 3, 3 and 6-studies exhibited data on the Immunoglobulin (Ig) A, IgG), Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6) levels. Heterogeneity was noted in all these outcomes (all I2 > 50.000%). The random-effects models indicated that compared with the control group, the IgA levels were increased by 0.463 standard deviation units (SMD = 0.463; 95% CI: 0.245, 0.681; p < 0.001); the IgG levels were increased by 0.521 standard deviation units (SMD = 0.521; 95% CI: 0.024, 1.019; p = 0.040), TNF-α levels were decreased by 1.693 Standard Deviation units (SMD = -1.693; 95% CI: -2.706, -0.680; p = 0.001) and IL-6 levels were decreased by 1.703 standard deviation units (SMD = -1.703; 95% CI: -2.185, -1.221; p < 0.001) in the experimental group (Fig. 7A‒D).Fig. 7Forest plots of immunity and inflammation-related parameters. Comparison of the IgA (A), IgG (B), TNF-α (C) and IL-6 (D) levels between the experimental and control groups. Ig, Immunoglobulin; TNF-α, Tumor Necrosis Factor-alpha (TNF-α); IL-6, Interleukin-6. Forest plots of immunity and inflammation-related parameters. Comparison of the IgA (A), IgG (B), TNF-α (C) and IL-6 (D) levels between the experimental and control groups. Ig, Immunoglobulin; TNF-α, Tumor Necrosis Factor-alpha (TNF-α); IL-6, Interleukin-6. Sensitivity analysis and publication bias Omitting any of the studies would not alter the outcomes of H. pylori eradication rate, total adverse event rate, diarrhea rate, nausea and vomiting rate, abdominal distension rate, poor appetite rate, abdominal pain rate, headache rate, bitter taste rate, rash rate, dizziness rate, IgA levels, TNF-α levels and IL-6 levels. However, the omission of the study of He et al. (2014) would alter the outcome of the constipation rate, the omission of the study of Liu et al. (2009) and Chen et al. (2019) would alter the outcome of the taste disorders rate, the omission of the study by Zhang et al. (2018) and Li et al. (2024) would alter the outcome of the IgG levels (Fig. 8A‒Q).Fig. 8Sensitivity analyses for all outcomes. Sensitivity analyses for H. pylori eradication rate. (A) Total adverse event rate (B), diarrhea rate (C), nausea and vomiting rate (D), abdominal distension rate (E), poor appetite rate (F), constipation rate (G), abdominal pain rate (H), taste disorder rate (I), headache rate (J), bitter taste rate (K), rash rate (L), dizziness rate (M), IgA (N), IgG (O), TNF-α (P), and IL-6 (Q) levels. H. pylori, Helicobacter pylori; Ig, immunoglobulin; TNF-α, Tumor Necrosis Factor-alpha (TNF-α); IL-6, Interleukin-6. Sensitivity analyses for all outcomes. Sensitivity analyses for H. pylori eradication rate. (A) Total adverse event rate (B), diarrhea rate (C), nausea and vomiting rate (D), abdominal distension rate (E), poor appetite rate (F), constipation rate (G), abdominal pain rate (H), taste disorder rate (I), headache rate (J), bitter taste rate (K), rash rate (L), dizziness rate (M), IgA (N), IgG (O), TNF-α (P), and IL-6 (Q) levels. H. pylori, Helicobacter pylori; Ig, immunoglobulin; TNF-α, Tumor Necrosis Factor-alpha (TNF-α); IL-6, Interleukin-6. No publication bias existed regarding the outcomes of H. pylori eradication rate, total adverse events rate, diarrhea rate, nausea and vomiting rate, abdominal distension rate, and constipation rate (p > 0.05) (Table 2).Table 2Publication bias.Indicatorsp-valueBias estimate (SE)H. pylori eradication rate0.070 (Peters’ test)57.85 (30.42)Total adverse events rate0.101 (Peters’ test)-94.70 (54.10)Diarrhea rate0.532 (Peters’ test)16.83 (26.39)Nausea and vomiting rate0.146 (Peters’ test)-88.16 (57.44)Abdominal distension rate0.979 (Peters’ test)-2.91 (107.73)Constipation rate0.326 (Peters’ test)-128.92 (124.72)SE, Standard Error. Table 2Publication bias.Indicatorsp-valueBias estimate (SE)H. pylori eradication rate0.070 (Peters’ test)57.85 (30.42)Total adverse events rate0.101 (Peters’ test)-94.70 (54.10)Diarrhea rate0.532 (Peters’ test)16.83 (26.39)Nausea and vomiting rate0.146 (Peters’ test)-88.16 (57.44)Abdominal distension rate0.979 (Peters’ test)-2.91 (107.73)Constipation rate0.326 (Peters’ test)-128.92 (124.72)SE, Standard Error. Publication bias. SE, Standard Error. Discussion H. pylori infection alters the structure and composition of the gastrointestinal microbiota by regulating the gastrointestinal microecological environment, cytokine production, antimicrobial peptides and immune response, which can further contribute to the development of gastrointestinal diseases.10,41 According to the international consensus, H. pylori should be eradicated promptly upon diagnosis.42 However, the H. pylori eradication rate is below 80% following conventional antibiotic-based therapies.9,43 Fortunately, the addition of probiotics to antibiotic-based therapies could improve H. pylori eradication.44 As reported by previous meta-analyses, probiotic-containing regimens achieved a higher H. pylori eradication than regimens without probiotics.45, 46, 47, 48 In line with these previous meta-analyses, the present study demonstrated that LCBE-containing interventions increased the H. pylori eradication rate compared with those without LCBE. It was speculated that LCBE may enhance H. pylori eradication by producing antimicrobial substances, strengthening the mucosal barrier and competing for adhesion sites.49 Subgroup analysis showed that LCBE in combination with triple or quadruple therapy was associated with higher H. pylori eradication rate compared with triple or quadruple therapy alone. These findings suggest that LCBE may have potential as an adjunctive component of conventional triple or quadruple therapy. In subgroups of daily doses of ≤ 1000 mg/day and 1500 mg/day, H. pylori eradication rate was increased in the experimental group compared to the control group. However, this trend was not found in the subgroup of daily doses of ≥ 2000 mg/day. These findings should be interpreted with caution and do not establish a confirmed dose-response relationship, as the non-significant result in the ≥ 2000 mg/day subgroup may be attributable to the limited number of available studies. Moreover, LCBE-containing interventions were associated with improved eradication rates in both the ≤ 2-week and > 2-week treatment duration subgroups, suggesting that the observed benefit was generally consistent across treatment durations. Overall, these subgroup analyses were exploratory and should be interpreted cautiously; further studies are warranted to validate the potential impact of treatment regimen, LCBE dosage, and treatment duration on the efficacy of LCBE-containing interventions. Antibiotic-based regimens for H. pylori infection often cause gut microbiota dysbiosis, which can lead to the occurrence of adverse events.3 Probiotics can alleviate adverse events, such as taste disturbance, diarrhea, nausea and constipation caused by antibiotics in patients with H. pylori infection.10 In the present meta-analysis, it was shown that the total adverse event rate was reduced by LCBE-containing interventions compared with those without LCBE in patients with H. pylori infection. This finding indicated that the addition of LCBE to conventional regimens improved safety profiles compared with conventional regimens alone in patients with H. pylori infection. In addition, gastrointestinal adverse events, including diarrhea rate, nausea and vomiting rate, abdominal distension rate, poor appetite rate and constipation rate, were lowered by LCBE-containing interventions compared with those without LCBE in patients with H. pylori infection. The potential explanation may be that LCBE could alleviate gut microbiota dysbiosis, thereby reducing gastrointestinal symptoms.50,51 Moreover, the taste disorder rate was also decreased by LCBE-containing interventions compared with those without LCBE. This finding was in line with previous meta-analyses.52,53 However, other non-gastrointestinal adverse events were not significantly different between patients with H. pylori infection receiving LCBE-containing interventions and those receiving interventions without LCBE. Therefore, the beneficial effect of LCBE on reducing adverse events may be related to its regulation of gut microbiota. In H. pylori infection, IgA aids the neutralization of pathogens and the maintenance of bacterial communities, while IgG aids in H. pylori clearance via immune activation and anti-bacterial activities.54 In the present meta-analysis, LCBE-containing interventions increased the IgA and IgG levels in patients with H. pylori infection. This finding suggested that LCBE may enhance immune defenses against H. pylori infection. Apart from immunity, inflammation also plays a crucial role in H. pylori infection.55 H. pylori infection triggers a cascade of pro-inflammatory responses characterized by upregulated expression levels of cytokines (such as TNF-α and IL-6), which contribute to the pathogenesis of gastrointestinal diseases.55 In the present meta-analysis, it was discovered that LCBE-containing interventions reduced TNF-α and IL-6 levels in patients with H. pylori infection. As explained by a previous study, LCBE may attenuate intestinal inflammation by enhancing fecal microbiome metabolism and the colonic barrier.12 The present meta-analysis contained several limitations. 1) It was disclosed that compared with conventional treatments, LCBE-containing interventions exhibited improved efficacy and safety in patients with H. pylori infection. However, it was unclear whether LCBE was superior to other probiotics in treating H. pylori infection. 2) The exploration of medication adherence was crucial for optimizing therapeutic outcomes. However, insufficient data from available studies hindered further exploration of this area. Additional studies should be conducted to compare the adherence between patients receiving intervention with or without LCBE. 3) LCBE-containing interventions increased IgA and IgG levels. However, the underlying mechanisms deserved to be investigated further. 4) The predominance of studies was conducted in China, which might limit the generalizability of our findings to other populations. In summary, LCBE-containing interventions are associated with higher eradication rates, fewer adverse events, and favorable changes in immune and inflammatory markers in patients with H. pylori infection. Authors’ contributions Chenghai Yang: Conceptualization; formal analysis; methodology; project administration; writing-original draft; writing-review & editing. Bingyun Lu: Data curation; investigation; resources; writing-original draft; writing-review & editing. Cangui Zhang: Data curation; investigation; resources; writing-original draft; writing-review & editing. Anjiang Wang: Data curation; investigation; resources; writing-original draft; writing-review & editing. Ye Chen: Conceptualization; Formal analysis; methodology; supervision; writing-original draft; writing-review & editing. Ethics approval Not applicable. Informed consent statement Not applicable. Funding This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (No. 82270581) and 10.13039/501100012235Baoan District Medical and Health Scientific Research Project of Shenzhen City (No. 2023JD240). Conflicts of interest The authors declare no conflicts of interest.